NVGN Novogen announces milestone with its super-benzopyran (:SBP) drug program; extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers (NVGN) : NVGN announced that it has achieved a key milestone with its super-benzopyran (:SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers.
News 
Market Data 
Discover 
